A head-to-head comparison of adalimumab and vedolizumab for the treatment of ulcerative colitis finds vedolizumab is superior for clinical remission and endoscopic improvement, but not in achieving corticosteroid remission.

The double-blinded trial — known as VARSITY and funded by Takeda, the maker of vedolizumab — was carried out in 245 centres across 34 countries, including Australia.